Incidence of any infection, severe and rare infections increased; risk higher for patients with severe versus mild psoriasis

However, the perception of overdiagnosis of melanocytic skin lesions does not impact diagnosing behaviors

Incidence of any infection, severe and rare infections increased; risk higher for patients with severe versus mild psoriasis

Lifestyle factors predict risk independent of genetic risk; relative impact of lifestyle factors greater than genetic risk

There are no FDA-approved or otherwise legally marketed over-the-counter skin lightening products

Treatment guidance mainly limited to antiviral advice, vaccination recommended as postexposure prophylaxis

Molecular signatures for inflammatory skin diseases can help with classification of clinically indeterminate skin rashes

Initial decrease across STDs reported during early part of 2020; decrease in chlamydia continued through 2020 but likely reflects underdiagnosis

Both Psoriasis Area and Severity Index and body surface area have limited capability for differentiating acceptable symptom state

Review of four studies shows significant difference in terms of scar width and Visual Analog Scale for BTXA group

Skin condition and itch significantly improved with ixekizumab through 108 weeks, with no new safety findings from 48 to 108 weeks

Increased herpes zoster risk found for those with versus without COVID-19, with more pronounced risk following COVID-19 hospitalization

The 2022 American Academy of Dermatology Annual Meeting

Incidence of melanoma thicker than 4 mm did not differ significantly for screened and unscreened patients

Incidence of melanoma thicker than 4 mm did not differ significantly for screened and unscreened patients

Clinically meaningful improvement reported in facial and total Vitiligo Area Scoring Index with ruxolitinib cream

Significantly more dupilumab-treated patients achieved ≥4-point reduction in 24h Worst-Itch Numeric Rating Scale at weeks 12 and 24

Patients receiving high-dose oral vitamin D3 prior to photodynamic therapy had improved clearance rates of facial AK

Lesion reduction seen by week 4, with continuous improvement over time; treatment-emergent adverse events mainly mild

Treatment persistence high with IL-17 inhibitors versus TNF inhibitors for psoriasis, psoriatic arthritis patients

Common allergens include rubber accelerators, preservatives, bisphenol A epoxy resin; service workers, machine operators affected most often

Abrocitinib, 200 mg daily, and upadacitinib, 30 mg daily, slightly better than dupilumab, while upadacitinib, 15 mg daily is similar to dupilumab

While weekly detection increased from March 2020 low, incidence rates have not fully recovered